{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:43:01Z","timestamp":1779154981508,"version":"3.51.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Department of Science and Technology - Philippine Council for Health Research and Development, Philippines"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02225-1","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:59:30Z","timestamp":1760014770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of genetic polymorphisms on drug response in Alzheimer\u2019s disease: a systematic review"],"prefix":"10.1186","volume":"18","author":[{"given":"Fresthel Monica M.","family":"Climacosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric David B.","family":"Ornos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole Clarence Louise L.","family":"Gapaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Gale R.","family":"Guantia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana Marie C.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Vincent M.","family":"Manalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almeera P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajina C.","family":"Carampel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joannes Luke B.","family":"Asis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Carlo B.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aira B.","family":"Dacasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeda Michelle M.","family":"Anlacan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"2","key":"2225_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"key":"2225_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz M, Silvestre S. Alzheimer\u2019s disease: recent treatment strategies. Eur J Pharmacol. 2020;887:173554.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"2225_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs. 2023;83(7):569\u201376.","journal-title":"Drugs"},{"key":"2225_CR4","unstructured":"Commissioner O of the. FDA. FDA. 2024 [cited 2025 Jul 3]. FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"issue":"2","key":"2225_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40120-019-00148-5","volume":"8","author":"AD Burke","year":"2019","unstructured":"Burke AD, Goldfarb D, Bollam P, Khokher S. Diagnosing and treating depression in patients with Alzheimer\u2019s disease. Neurol Ther. 2019;8(2):325\u201350.","journal-title":"Neurol Ther"},{"key":"2225_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pharmthera.2019.03.005","volume":"199","author":"A Eid","year":"2019","unstructured":"Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer\u2019s disease: a potential path to precision medicine. Pharmacol Ther. 2019;199:173\u201387.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2225_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ajhg.2008.10.008","volume":"83","author":"L Bertram","year":"2008","unstructured":"Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer\u2019s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623\u201332.","journal-title":"Am J Hum Genet"},{"issue":"14","key":"2225_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13142351","volume":"13","author":"B Ding","year":"2023","unstructured":"Ding B, Zhang X, Wan Z, Tian F, Ling J, Tan J, et al. Characterization of mitochondrial DNA methylation of Alzheimer\u2019s disease in plasma cell-free DNA. Diagnostics. 2023;13(14):2351.","journal-title":"Diagnostics"},{"issue":"3","key":"2225_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330.","journal-title":"Nat Genet"},{"issue":"1","key":"2225_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76849-x","volume":"10","author":"AO Giarratana","year":"2020","unstructured":"Giarratana AO, Zheng C, Reddi S, Teng SL, Berger D, Adler D, et al. APOE4 genetic polymorphism results in impaired recovery in a repeated mild traumatic brain injury model and treatment with Bryostatin-1 improves outcomes. Sci Rep. 2020;10(1):19919.","journal-title":"Sci Rep"},{"key":"2225_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00934","author":"J Lu","year":"2020","unstructured":"Lu J, Wang X, Wan L, Fu J, Huo Y, Zhao Y, et al. Gene polymorphisms affecting the pharmacokinetics and pharmacodynamics of donepezil efficacy. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00934.","journal-title":"Front Pharmacol"},{"key":"2225_CR12","unstructured":"The PRISMA. 2020 statement: an updated guideline for reporting systematic reviews | The BMJ [Internet]. [cited 2025 Jul 3]. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71"},{"issue":"6","key":"2225_CR13","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1002\/alz.12945","volume":"19","author":"TS Ellison","year":"2023","unstructured":"Ellison TS, Cappa SF, Garrett D, Georges J, Iwatsubo T, Kramer JH, et al. Outcome measures for Alzheimer\u2019s disease: a global inter-societal Delphi consensus. Alzheimers Dement. 2023;19(6):2707\u201329.","journal-title":"Alzheimers Dement"},{"key":"2225_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neulet.2015.12.062","volume":"614","author":"J Lu","year":"2016","unstructured":"Lu J, Fu J, Zhong Y, Chen P, Yang Q, Zhao Y, et al. The roles of Apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer\u2019s disease. Neurosci Lett. 2016;614:43\u20138.","journal-title":"Neurosci Lett"},{"issue":"4","key":"2225_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1176\/appi.neuropsych.21060160","volume":"34","author":"FF De Oliveira","year":"2022","unstructured":"De Oliveira FF, De Almeida SS, Chen ES, Smith MC, Bertolucci PHF. APOE \u03b54 carrier status as mediator of effects of psychotropic drugs on clinical changes in patients with alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci. 2022;34(4):351\u201360.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"3\u20134","key":"2225_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000342927","volume":"34","author":"HJ Han","year":"2012","unstructured":"Han HJ, Kim BC, Lee JY, Ryu SH, Na HR, Yoon SJ, et al. Response to Rivastigmine transdermal patch or memantine plus Rivastigmine patch is affected by Apolipoprotein E genotype in alzheimer patients. Dement Geriatr Cogn Disord. 2012;34(3\u20134):167\u201373.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2225_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000051238","author":"J Aerssens","year":"2001","unstructured":"Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2001. https:\/\/doi.org\/10.1159\/000051238.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2225_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2018.03.014","volume":"140","author":"J Lu","year":"2018","unstructured":"Lu J, Fu J, Zhong Y, Yang Q, Huang J, Li J, et al. Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with alzheimer\u2019s disease. Brain Res Bull. 2018;140:1\u20134.","journal-title":"Brain Res Bull"},{"issue":"1","key":"2225_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000329514","volume":"1","author":"M Zamani","year":"2011","unstructured":"Zamani M, Mehri M, Kollaee A, Yenki P, Ghaffarpor M, Harirchian MH, et al. Pharmacogenetic study on the effect of Rivastigmine on PS2 and APOE genes in Iranian alzheimer patients. Dement Geriatr Cogn Disord Extra. 2011;1(1):180\u20139.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"6","key":"2225_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/tpj.2010.61","volume":"11","author":"CE Patterson","year":"2011","unstructured":"Patterson CE, Todd SA, Passmore AP. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer\u2019s disease. Pharmacogenomics J. 2011;11(6):444\u201350.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"2225_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000124752","volume":"25","author":"SH Choi","year":"2008","unstructured":"Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC, et al. Effect of ApoE genotype on response to donepezil in patients with alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2008;25(5):445\u201350.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"2225_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000087371","volume":"20","author":"A Bizzarro","year":"2005","unstructured":"Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, et al. Apolipoprotein E \u03b54 allele differentiates the clinical response to donepezil in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2005;20(4):254\u201361.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2225_CR23","unstructured":"Babi\u0107 T, Mahovi\u0107 Lakusi\u0107 D, Serti\u0107 J, Petrovecki M, Stavljeni\u0107-Rukavina A. ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study. Coll Antropol. 2004;28(1):199\u2013204. PMID: 15636076."},{"issue":"5","key":"2225_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/sj.tpj.6500267","volume":"4","author":"M Farlow","year":"2004","unstructured":"Farlow M, Lane R, Kudaravalli S, He Y. Differential qualitative responses to Rivastigmine in APOE \u025b4 carriers and noncarriers. Pharmacogenomics J. 2004;4(5):332\u20135.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"2225_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-137","volume":"12","author":"ST Henderson","year":"2011","unstructured":"Henderson ST, Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer\u2019s disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet. 2011;12(1):137.","journal-title":"BMC Med Genet"},{"issue":"2","key":"2225_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/WAD.0b013e318299d096","volume":"28","author":"L Wang","year":"2014","unstructured":"Wang L, Day J, Roe CM, Brier MR, Thomas JB, Benzinger TL, et al. The effect of APOE \u03b54 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging. Alzheimer Dis Assoc Disord. 2014;28(2):122\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9","key":"2225_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1358\/mf.1999.21.9.795632","volume":"21","author":"XA Alvarez","year":"1999","unstructured":"Alvarez XA, Mouzo R, Pichel V, Al E. Double-blind placebo-controlled study with citicoline in apoegenotyped Alzheimer\u2019s disease patients. Effects on cognitiveperformance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999;21(9):633.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"9","key":"2225_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2","volume":"13","author":"SH Macgowan","year":"1998","unstructured":"Macgowan SH, Wilcock GK, Scott M. Effect of gender and Apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 1998;13(9):625\u201330.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"2225_CR29","doi-asserted-by":"publisher","first-page":"e13101","DOI":"10.1016\/j.neurobiolaging.2012.08.014","volume":"34","author":"A Ruiz","year":"2013","unstructured":"Ruiz A, Hern\u00e1ndez I, Ronsende-Roca M, Gonz\u00e1lez-P\u00e9rez A, Rodriguez-Noriega E, Ram\u00edrez-Lorca R, et al. Exploratory analysis of seven alzheimer\u2019s disease genes: disease progression. Neurobiol Aging. 2013;34(4):e13101\u20137.","journal-title":"Neurobiol Aging"},{"key":"2225_CR30","first-page":"209","volume":"12","author":"T Yaowaluk","year":"2019","unstructured":"Yaowaluk T, Senanarong V, Limwongse C, Boonprasert R, Kijsanayotin P. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with alzheimer\u2019s disease and vascular dementia. Pharmacogenomics Pers Med. 2019;12:209\u201324.","journal-title":"Pharmacogenomics Pers Med"},{"issue":"1","key":"2225_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JAD-142589","volume":"47","author":"JF Waring","year":"2015","unstructured":"Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, et al. APOE-\u025b4 carrier status and donepezil response in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2015;47(1):137\u201348.","journal-title":"J Alzheimers Dis"},{"key":"2225_CR32","doi-asserted-by":"publisher","unstructured":"Rigaud AS, Traykov L, Latour F, Couderc R, Moulin F, Forette F. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics. 2002;12(5):415\u201320. https:\/\/doi.org\/10.1097\/00008571-200207000-00009. PMID: 12142731.","DOI":"10.1097\/00008571-200207000-00009"},{"key":"2225_CR33","doi-asserted-by":"publisher","unstructured":"Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. Int J Neuropsychopharmacol. 2016;19(6):pyw024. https:\/\/doi.org\/10.1093\/ijnp\/pyw024. Epub 2016 Apr 7. PMID: 27207906; PMCID: PMC4926802.","DOI":"10.1093\/ijnp\/pyw024"},{"issue":"3","key":"2225_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0924-977X(02)00013-5","volume":"12","author":"B Borroni","year":"2002","unstructured":"Borroni B, Colciaghi F, Pastorino L, Archetti S, Corsini P, Cattabeni F, et al. ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol. 2002;12(3):195\u2013200.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2225_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2147\/NDT.S46689","volume":"9","author":"A Klimkowicz-Mrowiec","year":"2013","unstructured":"Klimkowicz-Mrowiec A, Wolkow P, Sado M, Dziubek A, Pera J, Dziedzic T, et al. Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2013;9:1029\u201333.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"2225_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3233\/JAD-2012-112123","volume":"30","author":"D Albani","year":"2012","unstructured":"Albani D, Martinelli Boneschi F, Biella G, Giacalone G, Lupoli S, Clerici F, et al. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer\u2019s disease patients. J Alzheimers Dis. 2012;30(4):745\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2225_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MAJ.0b013e318255a8f9","volume":"345","author":"Y Zhong","year":"2013","unstructured":"Zhong Y, Zheng X, Miao Y, Yan H, Wang B, Wan L. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with alzheimer\u2019s disease. Am J Med Sci. 2013;345(3):222\u20136.","journal-title":"Am J Med Sci"},{"issue":"10","key":"2225_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1212\/WNL.0b013e3181b6bbe3","volume":"73","author":"A Pilotto","year":"2009","unstructured":"Pilotto A, Franceschi M, D\u2019Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with alzheimer disease. Neurology. 2009;73(10):761\u20137.","journal-title":"Neurology"},{"issue":"2\u20133","key":"2225_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000082883","volume":"19","author":"PJ Visser","year":"2005","unstructured":"Visser PJ, Scheltens P, Pelgrim E, Verhey FRJ. Medial Temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with Rivastigmine in alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord. 2005;19(2\u20133):126\u201333.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"2225_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","volume":"6","author":"HH Feldman","year":"2007","unstructured":"Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer\u2019s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501\u201312.","journal-title":"Lancet Neurol"},{"key":"2225_CR41","unstructured":"Kane M. CYP2D6 Overview: Allele and Phenotype Frequencies. In: Medical Genetics Summaries [Internet] [Internet]. National Center for Biotechnology Information (US); 2025 [cited 2025 Jul 2]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574601\/"},{"issue":"1","key":"2225_CR42","first-page":"69","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med Off J Am Coll Med Genet. 2017;19(1):69\u201376.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"4","key":"2225_CR43","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688\u2013700.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2225_CR44","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"2225_CR45","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18636","volume":"12","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang Z, Wang Y, Jin W, Zhang Z, Jin L, et al. CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. PeerJ. 2024;12:e18636.","journal-title":"PeerJ"},{"issue":"3","key":"2225_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jphs.2015.10.010","volume":"129","author":"J Lu","year":"2015","unstructured":"Lu J, Wan L, Zhong Y, Yu Q, Han Y, Chen P, et al. Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with alzheimer\u2019s disease. J Pharmacol Sci. 2015;129(3):188\u201395.","journal-title":"J Pharmacol Sci"},{"issue":"1, Part 2","key":"2225_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jfma.2021.05.026","volume":"121","author":"PS Chou","year":"2022","unstructured":"Chou PS, Huang LC, Hour TC, Yen CW, Yang YH. Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer\u2019s disease. J Formos Med Assoc. 2022;121(1, Part 2):409\u201315.","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"2225_CR48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1533317519848237","volume":"34","author":"SL Ma","year":"2019","unstructured":"Ma SL, Tang NLS, Wat KHY, Tang JHY, Lau KH, Law CB, et al. Effect of CYP2D6 and CYP3A4 genotypes on the efficacy of cholinesterase inhibitors in Southern Chinese patients with alzheimer\u2019s disease. American Journal of Alzheimer\u2019s Disease & Other Dementias\u00ae. 2019;34(5):302\u20137.","journal-title":"American Journal of Alzheimer's Disease & Other Dementias\u00ae"},{"issue":"9","key":"2225_CR49","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","volume":"62","author":"F Varsaldi","year":"2006","unstructured":"Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer\u2019s disease patients. Eur J Clin Pharmacol. 2006;62(9):721\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"2225_CR50","first-page":"58","volume":"37","author":"N Sonali","year":"2013","unstructured":"Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V. Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2013;37(1\u20132):58\u201370.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"2225_CR51","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-011-1064-x","volume":"67","author":"C Chianella","year":"2011","unstructured":"Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, et al. BCHE and CYP2D6 genetic variation in alzheimer\u2019s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol. 2011;67(11):1147\u201357.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2225_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/cns.12036","volume":"19","author":"N Sonali","year":"2013","unstructured":"Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer\u2019s patients. CNS Neurosci Ther. 2013;19(2):91\u20137.","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"2225_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00228-010-0883-5","volume":"67","author":"L Magliulo","year":"2011","unstructured":"Magliulo L, Dahl ML, Lombardi G, Fallarini S, Villa LM, Biolcati A, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47\u201354.","journal-title":"Eur J Clin Pharmacol"},{"key":"2225_CR54","doi-asserted-by":"publisher","unstructured":"de Oliveira FF, Bertolucci PH, Chen ES, Smith MC. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J Alzheimers Dis. 2014;42 Suppl 3:S321\u20134. https:\/\/doi.org\/10.3233\/JAD-132189. PMID: 24577465.","DOI":"10.3233\/JAD-132189"},{"key":"2225_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2021.101443","volume":"26","author":"S Ben Halla","year":"2022","unstructured":"Ben Halla S, Tazzite A, Gazzaz B, Dehbi H, El Moutawakil B. The impact of ABCB1 gene polymorphism (C3435T) and its expression on response to donepezil in Moroccan patients with alzheimer\u2019s disease. Gene Rep. 2022;26:101443.","journal-title":"Gene Rep"},{"issue":"7","key":"2225_CR56","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1007\/s12035-015-9387-8","volume":"53","author":"M Zamani","year":"2016","unstructured":"Zamani M, Mohammadi M, Zamani H, Tavasoli A. Pharmacogenetic study on the impact of Rivastigmine concerning genetic variants of A2M and IL-6 genes on Iranian alzheimer\u2019s patients. Mol Neurobiol. 2016;53(7):4521\u20138.","journal-title":"Mol Neurobiol"},{"issue":"11","key":"2225_CR57","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","volume":"16","author":"R Blesa","year":"2006","unstructured":"Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer\u2019s disease. Pharmacogenet Genomics. 2006;16(11):771.","journal-title":"Pharmacogenet Genomics."},{"issue":"8","key":"2225_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/FPC.0b013e32832f8c17","volume":"19","author":"S Ferris","year":"2009","unstructured":"Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R. Progression from mild cognitive impairment to Alzheimer\u2019s disease: effects of sex, butyrylcholinesterase genotype, and Rivastigmine treatment. Pharmacogenet Genomics. 2009;19(8):635.","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"2225_CR59","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1007\/s12035-021-02295-z","volume":"58","author":"F Rezaei Rad","year":"2021","unstructured":"Rezaei Rad F, Ghahvechi Akbari M, Zamani M, Bayat S, Zamani M. Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer\u2019s Disease. Mol Neurobiol. 2021;58(6):2792\u2013802.","journal-title":"Mol Neurobiol."},{"issue":"6","key":"2225_CR60","doi-asserted-by":"publisher","first-page":"1711.e7","DOI":"10.1016\/j.neurobiolaging.2012.12.008","volume":"34","author":"F Martinelli-Boneschi","year":"2013","unstructured":"Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, Santangelo R, et al. Pharmacogenomics in Alzheimer\u2019s disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiol Aging. 2013;34(6):1711.e7-1711.e13.","journal-title":"Neurobiol Aging."},{"issue":"10","key":"2225_CR61","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s12031-020-01588-7","volume":"70","author":"FF de Oliveira","year":"2020","unstructured":"de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer\u2019s Disease. J Mol Neurosci. 2020;70(10):1574\u201388.","journal-title":"J Mol Neurosci."},{"issue":"2","key":"2225_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/00129785-200404020-00006","volume":"4","author":"DM Weiner","year":"2004","unstructured":"Weiner DM, Goodman MW, Colpitts TM, Feddock MA, Duggento KL, Nash NR, et al. Functional Screening of Drug Target Genes. Am J Pharmacogenomics. 2004;4(2):119\u201328.","journal-title":"Am J Pharmacogenomics."},{"issue":"12","key":"2225_CR63","doi-asserted-by":"publisher","first-page":"e84059","DOI":"10.1371\/journal.pone.0084059","volume":"8","author":"PH Weng","year":"2013","unstructured":"Weng PH, Chen JH, Chen TF, Sun Y, Wen LL, Yip PK, et al. CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer\u2019s Disease. PLOS ONE. 2013;8(12):e84059.","journal-title":"PLOS ONE."},{"issue":"4","key":"2225_CR64","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3233\/JAD-160074","volume":"52","author":"F Clarelli","year":"2016","unstructured":"Clarelli F, Mascia E, Santangelo R, Mazzeo S, Giacalone G, Galimberti D, et al. Chrna7 gene and response to cholinesterase inhibitors in an Italian cohort of Alzheimer\u2019s disease patients. J Alzheimers Dis. 2016;52(4):1203\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2225_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1533317514539540","volume":"30","author":"ILS Braga","year":"2015","unstructured":"Braga ILS, Silva PN, Furuya TK, Santos LC, Pires BC, Mazzotti DR, et al. Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer\u2019s disease. American Journal of Alzheimer\u2019s Disease & Other Dementias\u00ae. 2015;30(2):139\u201344.","journal-title":"American Journal of Alzheimer's Disease & Other Dementias\u00ae"},{"key":"2225_CR66","doi-asserted-by":"crossref","unstructured":"Szigeti K, Ihnatovych I, Birkaya B, Chen Z, Ouf A, Indurthi DC, et al. CHRFAM7A: A human specific fusion gene, accounts for the translational gap for cholinergic strategies in Alzheimer\u2019s disease. eBioMedicine [Internet]. 2020 Sep 1 [cited 2025 Jul 4];59. Available from: https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(20)30267-X\/fulltext","DOI":"10.1016\/j.ebiom.2020.102892"},{"key":"2225_CR67","first-page":"111","volume":"25","author":"H Yoon","year":"2015","unstructured":"Yoon H, Myung W, Lim SW, Kang HS, Kim S, Won HH, et al. Association of the Choline Acetyltransferase Gene with Responsiveness to Acetylcholinesterase Inhibitors in Alzheimer\u2019s Disease. Pharmacopsychiatry. 2015;25:111\u20137.","journal-title":"Pharmacopsychiatry."},{"issue":"2","key":"2225_CR68","doi-asserted-by":"publisher","first-page":"168","DOI":"10.9758\/cpn.2015.13.2.168","volume":"13","author":"KU Lee","year":"2015","unstructured":"Lee KU, Lee JH, Lee DY, Youn JC, Kim JL, Moon SW, et al. The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer\u2019s Disease. Clin Psychopharmacol Neurosci. 2015;13(2):168\u201373.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"2","key":"2225_CR69","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.fpc.0000189799.88596.04","volume":"16","author":"D Harold","year":"2006","unstructured":"Harold D, MacGregor S, Patterson CE, Hollingworth P, Moore P, Owen MJ, et al. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Pharmacogenet Genomics. 2006;16(2):75.","journal-title":"Pharmacogenet Genomics"},{"key":"2225_CR70","unstructured":"Nordquist H, Jamil RT, Biochemistry. HLA Antigens. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jul 8]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546662\/"},{"issue":"6","key":"2225_CR71","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/11588720-000000000-00000","volume":"41","author":"Z Puthucheary","year":"2011","unstructured":"Puthucheary Z, Skipworth JRA, Rawal J, Loosemore M, Van Someren K, Montgomery HE. The ACE gene and human performance: 12 years on. Sports Med. 2011;41(6):433\u201348.","journal-title":"Sports Med"},{"issue":"3","key":"2225_CR72","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.apsb.2022.01.011","volume":"12","author":"CT Lewandowski","year":"2022","unstructured":"Lewandowski CT, Laham MS, Thatcher GRJ. Remembering your A, B, c\u2019s: alzheimer\u2019s disease and ABCA1. Acta Pharm Sin B. 2022;12(3):995\u20131018.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2225_CR73","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-025-06272-1","volume":"23","author":"T Decaix","year":"2025","unstructured":"Decaix T, Bouaziz-Amar E, Paquet C, Lilamand M. Revisiting ABCB1 polymorphism: a missing piece in Alzheimer\u2019s risk and treatment? J Transl Med. 2025;23(1):252.","journal-title":"J Transl Med"},{"key":"2225_CR74","unstructured":"PubChem. CHRNA7 - cholinergic receptor nicotinic alpha 7 subunit (human) [Internet]. [cited 2025 May 6]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/gene\/CHRNA7\/human"},{"key":"2225_CR75","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.neuropharm.2015.02.006","volume":"96","author":"ML Sinkus","year":"2015","unstructured":"Sinkus ML, Graw S, Freedman R, Ross RG, Lester HA, Leonard S. The human CHRNA7 and CHRFAM7A genes: a review of the genetics, regulation, and function. Neuropharmacology. 2015;96:274\u201388.","journal-title":"Neuropharmacology"},{"issue":"8","key":"2225_CR76","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.neurobiolaging.2007.11.003","volume":"30","author":"A Barabash","year":"2009","unstructured":"Barabash A, Marcos A, Anc\u00edn I, V\u00e1zquez-Alvarez B, De Ugarte C, Gil P, et al. APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer\u2019s disease. Neurobiol Aging. 2009;30(8):1254\u201364.","journal-title":"Neurobiol Aging"},{"key":"2225_CR77","unstructured":"CHRM1 cholinergic receptor muscarinic 1 [Homo sapiens (human)] - Gene - NCBI [Internet]. [cited 2025 May 13]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/1128"},{"key":"2225_CR78","unstructured":"PubChem. CHAT - choline O-acetyltransferase (human) [Internet]. [cited 2025 May 14]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/gene\/CHAT\/human"},{"issue":"2","key":"2225_CR79","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neulet.2004.05.041","volume":"366","author":"KW Kim","year":"2004","unstructured":"Kim KW, Suh YJ, Park WY, Jhoo JH, Lee DY, Youn JC, et al. Choline acetyltransferase G +4 A polymorphism confers a risk for Alzheimer\u2019s disease in concert with Apolipoprotein E \u03b54. Neurosci Lett. 2004;366(2):182\u20136.","journal-title":"Neurosci Lett"},{"issue":"1","key":"2225_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000140612","volume":"26","author":"M Tang","year":"2008","unstructured":"Tang M, Rao D, Ma C, Guo Y, Han H, Ling K, et al. Evaluation of choline acetyltransferase gene polymorphism (2384 G\/A) in Alzheimer\u2019s disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;26(1):9\u201314.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2225_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.115195","volume":"220","author":"SA Khan","year":"2023","unstructured":"Khan SA, Leonel Javeres MN, Abbas Shah ST, Bibi N, Muneer Z, Hussain S, et al. Dysregulation of butyrylcholinesterase, BCHE gene SNP rs1803274, and pro-inflammatory cytokines in occupational workers. Environ Res. 2023;220:115195.","journal-title":"Environ Res"},{"key":"2225_CR82","unstructured":"PubChem. BCHE - butyrylcholinesterase (human) [Internet]. [cited 2025 Jul 8]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/gene\/BCHE\/human"},{"key":"2225_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00604","volume":"7","author":"Y Luo","year":"2016","unstructured":"Luo Y, Zheng SG. Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol. 2016;7:604.","journal-title":"Front Immunol"},{"key":"2225_CR84","unstructured":"LDLR low density lipoprotein receptor. [Homo sapiens (human)] - Gene - NCBI [Internet]. [cited 2025 Jul 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/3949"},{"issue":"5","key":"2225_CR85","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/ana.25350","volume":"84","author":"MS Mulhern","year":"2018","unstructured":"Mulhern MS, Stumpel C, Stong N, Brunner HG, Bier L, Lippa N, et al. NBEA: developmental disease gene with early generalized epilepsy phenotypes. Ann Neurol. 2018;84(5):788\u201395.","journal-title":"Ann Neurol"},{"key":"2225_CR86","unstructured":"Prkce protein kinase C. epsilon [Rattus norvegicus (Norway rat)] - Gene - NCBI [Internet]. [cited 2025 Jul 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/29340"},{"issue":"9","key":"2225_CR87","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/s41380-024-02502-y","volume":"29","author":"O Saha","year":"2024","unstructured":"Saha O, Melo de Farias AR, Pelletier A, Siedlecki-Wullich D, Landeira BS, Gadaut J, et al. The alzheimer\u2019s disease risk gene BIN1 regulates activity-dependent gene expression in human-induced glutamatergic neurons. Mol Psychiatry. 2024;29(9):2634\u201346.","journal-title":"Mol Psychiatry"},{"issue":"10","key":"2225_CR88","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1038\/cddis.2011.99","volume":"2","author":"KA Chaiwatanasirikul","year":"2011","unstructured":"Chaiwatanasirikul KA, Sala A. The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death Dis. 2011;2(10):e219.","journal-title":"Cell Death Dis"},{"key":"2225_CR89","unstructured":"PICALM phosphatidylinositol binding clathrin assembly. protein [Homo sapiens (human)] - Gene - NCBI [Internet]. [cited 2025 Jul 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/8301"},{"key":"2225_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102014","volume":"88","author":"J Gaugel","year":"2024","unstructured":"Gaugel J, Haacke N, Sehgal R, J\u00e4hnert M, Jonas W, Hoffmann A, et al. Picalm, a novel regulator of GLUT4-trafficking in adipose tissue. Mol Metab. 2024;88:102014.","journal-title":"Mol Metab"},{"issue":"11","key":"2225_CR91","volume":"12","author":"C Watanabe","year":"2022","unstructured":"Watanabe C, Shibuya H, Ichiyama Y, Okamura E, Tsukiyama-Fujii S, Tsukiyama T, et al. Essential roles of exocyst complex component 3-like 2 on cardiovascular development in mice. Life (Basel). 2022;12(11):1730.","journal-title":"Life (Basel)"},{"key":"2225_CR92","unstructured":"ResearchGate [Internet]. [cited 2025 Jul 8]. Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease. Available from: https:\/\/www.researchgate.net\/publication\/322403193_Human_complement_receptor_type_1_CR1_protein_levels_and_genetic_variants_in_chronic_Chagas_Disease"},{"issue":"2","key":"2225_CR93","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12035-014-8723-8","volume":"51","author":"XC Zhu","year":"2015","unstructured":"Zhu XC, Yu JT, Jiang T, Wang P, Cao L, Tan L. CR1 in alzheimer\u2019s disease. Mol Neurobiol. 2015;51(2):753\u201365.","journal-title":"Mol Neurobiol"},{"key":"2225_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1481494","volume":"15","author":"X Luo","year":"2024","unstructured":"Luo X, Luo B, Fei L, Zhang Q, Liang X, Chen Y, et al. MS4A superfamily molecules in tumors, Alzheimer\u2019s and autoimmune diseases. Front Immunol. 2024;15:1481494.","journal-title":"Front Immunol"},{"key":"2225_CR95","unstructured":"Structure, function, and regulation of insulin-degrading enzyme - PubMed [Internet]. [cited 2025 Jul 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19251053\/"},{"issue":"1","key":"2225_CR96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.brainresrev.2008.12.020","volume":"60","author":"K Ren","year":"2009","unstructured":"Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev. 2009;60(1):57\u201364.","journal-title":"Brain Res Rev"},{"issue":"6","key":"2225_CR97","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","volume":"45","author":"A Rowland","year":"2013","unstructured":"Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121\u201332.","journal-title":"Int J Biochem Cell Biol."},{"issue":"4","key":"2225_CR98","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"ME Risner","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J. 2006;6(4):246\u201354.","journal-title":"Pharmacogenomics J."}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02225-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T14:03:35Z","timestamp":1760018615000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02225-1","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}